INVOLVEMENT OF RESIDUES 296-299 IN THE ENZYMATIC-ACTIVITY OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR

被引:18
作者
PAONI, NF
REFINO, CJ
BRADY, K
PENA, LC
NGUYEN, HV
KERR, EM
JOHNSON, AC
WURM, FM
VANREIS, R
BOTSTEIN, D
BENNETT, WF
机构
[1] GENENTECH INC,DEPT CARDIOVASC RES,460 POINT SAN BRUNO BLVD,SAN FRANCISCO,CA 94080
[2] GENENTECH INC,DEPT CELL CULTURE RES & DEV,SAN FRANCISCO,CA 94080
[3] GENENTECH INC,DEPT RECOVERY RES & DEV,SAN FRANCISCO,CA 94080
[4] STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305
来源
PROTEIN ENGINEERING | 1992年 / 5卷 / 03期
关键词
TISSUE-TYPE PLASMINOGEN ACTIVATOR; MUTAGENESIS; FIBRINOLYSIS;
D O I
10.1093/protein/5.3.259
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tetra-alanine substitution variant KHRR 296-299 AAAA of tissue-type plasminogen activator (t-PA) was previously shown to have enhanced fibrin specificity and enhanced activity in the presence of fibrin compared with the wild-type form of the molecule. The structural requirements for these alterations in enzymatic activity were investigated by constructing several amino acid substitution variants at each of the positions from 296 to 299 and evaluating their activities under a variety of conditions. Effects on plasminogen activator activity were common among the point mutants at positions 296-299; nearly all had a phenotype similar to the KHRR 296-299 AAAA variant. The greatest effects on enzymatic function were found with multiple substitution variants, but some single charge reversals and proline substitutions had substantial effects. The enhanced fibrin specificity of KHRR 296-299 AAAA t-PA results in less fibrinogenolysis than seen with wild-type t-PA. Approximately four times greater concentration of KHRR 296-299 AAAA compared with wild-type t-PA was required to consume 50% of the fibrinogen in human plasma.
引用
收藏
页码:259 / 266
页数:8
相关论文
共 15 条
[1]  
BENNETT WF, 1991, J BIOL CHEM, V266, P5191
[2]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
[3]  
EASTMAN D, 1991, BIOCHEMISTRY-US, V31, P419
[4]  
GARDELL SJ, 1990, BLOOD, V76, P2560
[5]  
GARDELL SJ, 1989, J BIOL CHEM, V264, P17947
[6]   EFFECTIVE THROMBOLYSIS WITHOUT MARKED PLASMINEMIA AFTER BOLUS INTRAVENOUS ADMINISTRATION OF VAMPIRE BAT SALIVARY PLASMINOGEN-ACTIVATOR IN RABBITS [J].
GARDELL, SJ ;
RAMJIT, DR ;
STABILITO, II ;
FUJITA, T ;
LYNCH, JJ ;
CUCA, GC ;
JAIN, D ;
WANG, SP ;
TUNG, J ;
MARK, GE ;
SHEBUSKI, RJ .
CIRCULATION, 1991, 84 (01) :244-253
[7]  
HEYNEKER HL, 1983, Patent No. 831036298
[8]  
HIGGINS DL, 1990, ANNU REV PHARMACOL, V30, P91
[9]   AMINO-ACID-RESIDUES THAT AFFECT INTERACTION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR WITH PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
MADISON, EL ;
GOLDSMITH, EJ ;
GERARD, RD ;
GETHING, MJH ;
SAMBROOK, JF ;
BASSELDUBY, RS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (09) :3530-3533
[10]   SERPIN-RESISTANT MUTANTS OF HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
MADISON, EL ;
GOLDSMITH, EJ ;
GERARD, RD ;
GETHING, MJH ;
SAMBROOK, JF .
NATURE, 1989, 339 (6227) :721-724